Our History

Download Brochure

Our History

Shilpa Medicare has been on path of expansion ever since its inception in 1987. With a regulatory recognized manufacturing set up and excellent scientific expert team in place, Shilpa Medicare has since been on a steady growth path. Currently we are one of the leaders in the Oncology market and offer a complete range of products in this segment spanning across APIs, formulations both in terms of R&D and manufacturing capabilities. Further to consolidation in field of oncology API and formulations, we are striving to put in our efforts in field of novel drug delivery systems and biotech products along with widening our focus to other therapy areas. Where we are today has been the result of our constant endeavors for more than two decades. We are proud to share our journey from being a small start-up to a well-recognized establishment …



Shilpa Medicare Ltd. established as Shilpa Antibiotics Ltd.


Shilpa Medicare Ltd. started its first commercial production of Trimethoprim.


Antibacterial products manufacturing started for companies such as Bombay Drug House Pvt Ltd and GlaxoSmithKline Pharmaceuticals Ltd.

New production facilities inducted for the manufacture of Sodium methoxide by indigenously developed technology.


Shilpa Medicare was converted into a Public Limited Company


Shilpa Medicare was listed on Bombay Stock Exchange on Jun 19, 1995


First patent application filed


Shilpa Medicare acquired 100% stake in Loba Feinchemie GmbH, Austria


Govt. of India awarded 'Best Entrepreneur Award' to Mr. Vishnukant, MD-Shilpa Medicare.

  • Also - "Emerging India Runner Award” given by CNBC.
  • Also -"Star Export House" Status from Ministry of Commerce and Industry, Govt. of India.


Shilpa Medicare listed on National Stock Exchange (NSE) on Dec 03, 2009.

  • Shilpa Medicare entered 50:50 joint venture with Industria Chimica SRL, Italy (ICE) and Prodotti Chini Alimetari SpA, Italy (PCA).
  • First DMF filed for Oncology API- Anastrozole.


Shilpa Medicare successfully set up a 100% EOU project incurring a capital expenditure of nearly Rs. 1000 million.

  • RaichemLifesciencesPvt Ltd secured ISO 9001:2008 certification
  • ‘Best District Export Award’ given by FKCCI, Bangalore
  • “Star Export Excellence Award” given by VITC, Bangalore


Shilpa Medicare acquired a controlling stake in Hyderabad-based “Shilpa Therapeutics”

  • “State of Art R&D center established in Vizag and started its operations
  • “M/s Raichem Life Sciences Private Limited, a 100% subsidiary of Shilpa Medicare Ltd., merged with Shilpa Medicare Ltd.
  • “US operations started


National Energy Conservation Award (Ist Prize in drugs & pharmaceuticals sector), by President of INDIA.


Shilpa Medicare Formulations facility (Manufacturing of Oral & Injectible (Onco Products) at Pharma Park Jadcherla (SEZ), near Mahaboobnagar (Telangana) became fully operational.